Skip to main content
VCbacked
Log inGet Started

TOLREMO therapeutics

Zúrich, Switzerland

TOLREMO therapeutics is a developer of small molecules intended to target novel drug resistance pathways in cancer therapy.

$37.9M raised
Sep 2023
Series A
BiotechnologyPharmaceutical

Top Investors

Zúrcher Kantonal BankAltos VenturesredalpineBioMedPartnersPierre Fabre Invest

Founder Contacts

19,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about TOLREMO therapeutics

How much funding has TOLREMO therapeutics raised?
TOLREMO therapeutics has raised $37.9M in total funding. The most recent round was Series A. The last funding was announced in September 2023.
Who are TOLREMO therapeutics's investors?
TOLREMO therapeutics's investors include Zúrcher Kantonal Bank, Altos Ventures, redalpine, BioMedPartners, Pierre Fabre Invest.
Where is TOLREMO therapeutics headquartered?
TOLREMO therapeutics is headquartered in Zúrich, Switzerland.
What does TOLREMO therapeutics do?
TOLREMO therapeutics is a developer of small molecules intended to target novel drug resistance pathways in cancer therapy.
What stage is TOLREMO therapeutics at?
TOLREMO therapeutics is at the Series A stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"TOLREMO therapeutics — Funding & Investors." VCBacked, September 20, 2023, https://www.vcbacked.co/company/tolremo-therapeutics. Accessed June 16, 2026.
APA
VCBacked. (2023). TOLREMO therapeutics — Funding & Investors. Retrieved June 16, 2026, from https://www.vcbacked.co/company/tolremo-therapeutics
Wikipedia (cite web)
{{cite web |title=TOLREMO therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/tolremo-therapeutics |website=VCBacked |access-date=June 16, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Biotechnology

View all
Virtuoso Surgical
Nashville
Pharvaris
Zug
Odyssey Therapeutics
Boston$213.0M
Tempus
Chicago
Anagram Therapeutics
Boston
Prenetics
Hong Kong